A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer.
Julie E BaumanZhengjia ChenChao ZhangJames P OhrRobert L FerrisGerald M McGoriskStephen BrandtSumathi SrivatsaAmy Y ChenConor E SteuerDong M ShinNabil F SabaFadlo R KhuriTaofeek Kunle OwonikokoPublished in: Cancers (2022)
The combination of everolimus and pasireotide-LAR showed promising efficacy over single agent. The delayed combination of everolimus and pasireotide-LAR following progression on single agent everolimus appeared intriguing as a combination strategy.